Northern Trust Corp Increases Stock Holdings in MEI Pharma, Inc. (NASDAQ:MEIP)

Northern Trust Corp increased its position in MEI Pharma, Inc. (NASDAQ:MEIP) by 54.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 35,596 shares of the company’s stock after purchasing an additional 12,561 shares during the period. Northern Trust Corp owned 0.53% of MEI Pharma worth $88,000 at the end of the most recent quarter.

Separately, Virtu Financial LLC acquired a new stake in shares of MEI Pharma during the fourth quarter worth $26,000. Institutional investors and hedge funds own 52.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen initiated coverage on MEI Pharma in a report on Sunday, May 18th. They issued a “buy” rating for the company.

MEI Pharma Price Performance

NASDAQ MEIP opened at $2.15 on Wednesday. The firm has a market capitalization of $14.32 million, a P/E ratio of -0.38 and a beta of 0.21. MEI Pharma, Inc. has a 1-year low of $1.46 and a 1-year high of $4.10. The business’s 50-day simple moving average is $2.06 and its 200-day simple moving average is $2.43.

MEI Pharma (NASDAQ:MEIP) last announced its earnings results on Tuesday, May 13th. The company reported ($0.39) earnings per share (EPS) for the quarter. On average, equities research analysts expect that MEI Pharma, Inc. will post -5.1 EPS for the current fiscal year.

MEI Pharma Company Profile

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.